As Bristol Myers Squibb attempts to convert two accelerated oncology nods for Krazati into traditional FDA approvals, the company has detailed what could be a major stumble in the KRAS G12C inhibitor’s smaller-opportunity indication of colorectal cancer.
Source: FiercePharma
